Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

NUDT1 PROTAC for MYC-driven cancers

BC Staff
May 31, 2024 11:14 PM UTC

A proteolytic targeting chimera (PROTAC) that degrades NUDT1 — a hydrolase that prevents the incorporation of oxidized nucleotides into DNA, which decreases DNA damage and promotes survival in response to MYC amplification — could help treat MYC-driven cancers.

In a human neuroblastoma cell line with an inducible MYC amplification, a CRISPR/Cas9 loss-of-function metabolism screen identified NUDT1 as the top MYC-driven metabolic dependency...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Wuhan University